Interferon-γ and intimal hyperplasia

Circulation Research

Volumn 101, Issue 6, 2007, Pages 542-544

  Rose, Marlene L ^a,b  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

^b HAREFIELD HOSPITAL   (United Kingdom)

Author keywords

Arteriosclerosis; Neointima

Indexed keywords

GAMMA INTERFERON; 2 MORPHOLINO 8 PHENYLCHROMONE; 2-(4-MORPHOLINYL)-8-PHENYL-4H-1-BENZOPYRAN-4-ONE; CHROMONE DERIVATIVE; ENZYME INHIBITOR; IMMUNOSUPPRESSIVE AGENT; MORPHOLINE DERIVATIVE; MTORC1 PROTEIN, HUMAN; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN; RAPAMYCIN; RAPTOR PROTEIN, HUMAN; RIBOSOMAL PROTEIN S6 KINASE, 70KD, POLYPEPTIDE 1; S6 KINASE; TRANSCRIPTION FACTOR; UNCLASSIFIED DRUG;

ATHEROSCLEROSIS; CELL INTERACTION; CELL PROLIFERATION; EDITORIAL; HEART FAILURE; HEART TRANSPLANTATION; HUMAN; HYPERPLASIA; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; SURVIVAL TIME; ADENOVIRUS; ANIMAL; CORONARY ARTERY ATHEROSCLEROSIS; CORONARY BLOOD VESSEL; DRUG ANTAGONISM; DRUG EFFECT; ENZYMOLOGY; GENE TRANSFER; GENETICS; GRAFT REJECTION; INTIMA; METABOLISM; MOUSE; MOUSE MUTANT; NOTE; PATHOLOGY; PHOSPHORYLATION; TIME; TRANSPLANTATION; VASCULAR SMOOTH MUSCLE; XENOGRAFT;

1-PHOSPHATIDYLINOSITOL 3-KINASE; ADENOVIRIDAE; ANIMALS; CELL PROLIFERATION; CHROMONES; CORONARY ARTERIOSCLEROSIS; CORONARY VESSELS; ENZYME INHIBITORS; GENE TRANSFER TECHNIQUES; GRAFT REJECTION; HUMANS; HYPERPLASIA; IMMUNOSUPPRESSIVE AGENTS; INTERFERON TYPE II; MICE; MICE, SCID; MORPHOLINES; MUSCLE, SMOOTH, VASCULAR; PHOSPHORYLATION; PROTEINS; RIBOSOMAL PROTEIN S6 KINASES, 70-KDA; SIROLIMUS; TIME FACTORS; TRANSCRIPTION FACTORS; TRANSPLANTATION, HETEROLOGOUS; TUNICA INTIMA;

EID: 34748863570     PISSN: 00097330     EISSN: None     Source Type: Journal    
DOI: 10.1161/CIRCRESAHA.107.160911     Document Type: Editorial

References (18)

1. Boehm U, Klamp T, Groot M, Howard JC. Cellular responses to interferon-gamma. Annu Rev Immunol 1997;15:749-795
2. Leon ML, Zuckerman SH. Gamma interferon: a central mediator in atherosclerosis. Inflamm Res 2005;54:395-411.
3. Wang Y, Bai Y, Qin L, Zhang P, Yi T, Teesdale SA, Zhao L, Pober JS, Tellides G. Interferon-{gamma} induces human vascular smooth muscle cell proliferation and intimal expansion by phosphatidylinositol 3-kinase dependent mammalian target of rapamycin raptor complex 1 activation. Circ Res. 2007;101:560-569.
4. Taylor DO, Edwards LB, Boucek MM, Trulock EP, Waltz DA, Keck BM, Hertz MI. Registry of the International Society for Heart and Lung Transplantation: twenty-third official adult heart transplantation report-2006. J Heart Lung Transplant. 2006;25:869-879.
5. Rahmani M, Cruz RP, Granville DJ, McManus BM. Allograft vasculopathy versus atherosclerosis. Circ Res. 2006:99:801-815.
6. Eisen HJ, Tuzcu EM, Dorent R, Kobashigawa J, Mancini D, Valantine-von Kaeppler HA, Starling RC, Sorensen K, Hummel M, Lind JM, Abeywickrama KH, Bernhardt P, RAD B253 Study Group. Everolimus for the prevention of allograft rejection and vasculopathy in cardiac-transplant recipients. N Engl J Med 2003;349:847-858.
7. Marx SO, Marks AR. Bench to bedside: the development of rapamycin and its application to stent restenosis Circulation. 2001;104:852-855.
8. Easton JB, Houghton PJ. Therapeutic potential of target of rapamycin inhibitors. Expert Opin Ther Targets. 2004;8:551-564.
9. Tellides G, Tereb DA, Kirkiles-Smith NC, Kim RW, Wilson JH, Schechner JS, Lorber MI, Pober JS. Interferon-gamma elicits arteriosclerosis in the absence of leukocytes. Nature. 2000;403:207-211.
10. Wang Y, Burns WR, Tang PC, Yi T, Schechner JS, Zerwes HG, Sessa WC, Lorber MI, Pober JS, Tellides G. Interferon-gamma plays a nonredundant role in mediating T cell-dependent outward vascular remodeling of allogeneic human coronary arteries. FASEB J. 2004;18:606-608.
11. Ruggero D, Sonenberg N. The Akt of translational control Oncogene. 2005;24:7426-7434.
12. Nagano H, Mitchell RN, Taylor MK, Hasegawa S, Tilney NL, Libby P. Interferon-gamma deficiency prevents coronary arteriosclerosis but not myocardial rejection in transplanted mouse hearts. J Clin Invest. 1997;100:550-557.
13. Raisanen-Sokolowski A, Glysing-Jensen T, Koglin J, Russell ME. Reduced transplant arteriosclerosis in murine cardiac allografts placed in interferon-gamma knockout recipients. Am J Pathol. 1998;152:359-365.
14. van Loosdregt J, van Oosterhout MF, Bruggink AH, van Wichen DF, van Kuik J, de Koning E, Baan CC, de Jonge N, Gmelig-Meyling FH, de Weger RA. The chemokine and chemokine receptor profile of infiltrating cells in the wall of arteries with cardiac allograft vasculopathy is indicative of a memory T-helper 1 response. Circulation. 2006;114:1599-1607.
15. Choi J, Enis DR, Koh KP, Shiao SL, Pober JS. T lymphocyte-endothelial cell interactions. Annu Rev Immunol. 2004;22:683-709.
16. Schroder K, Hertzog PJ, Ravasi T, Hume DA. Interferon-gamma: an overview of signals, mechanisms and functions. J Leukoc Biol. 2004;75:163-189.
17. Lepin EJ, Zhang Q, Zhang X, Jindra PT, Hong LS, Ayele P, Peralta MV, Gjertson DW, Kobashigawa JA, Wallace WD, Fishbein MC, Reed EF. Phosphorylated S6 ribosomal protein: a novel biomarker of antibody-mediated rejection in heart allografts. Am J Transplant. 2006;6:1560-1571.
18. Wehner J, Morrell CN, Reynolds T, Rodriguez ER, Baldwin WM III. Antibody and complement in transplant vasculopathy Circ Res. 2007;100:191-203.